Novartis AG (NOT.F) Stock Price, News & Chart

	NOT.F	AMGN	AZN	BIIB	MRK	SNY
Market cap	260.13B	237.31B	261.82B	35.92B	365.88B	99.20B
P/E (TTM)	24.4	27.3	25.2	43.2	117.7	21.8
Forward P/E	—	17.9	14.9	14.8	16.0	7.8
Price/book	7.0	20.3	5.2	1.9	8.7	1.3
Dividend yield	3.02%	2.30%	1.90%	—	2.29%	5.84%
1-year change	+17.76%	+45.76%	+1.43%	+64.57%	+69.27%	−16.63%
Today	+0.88%	+3.29%	+2.97%	+4.12%	+3.25%	+4.62%

Market cap

260.13B

237.31B

261.82B

35.92B

365.88B

99.20B

P/E (TTM)

24.4

27.3

25.2

43.2

117.7

21.8

Forward P/E

—

17.9

14.9

14.8

16.0

7.8

Price/book

7.0

20.3

5.2

1.9

8.7

1.3

Dividend yield

3.02%

2.30%

1.90%

—

2.29%

5.84%

1-year change

+17.76%

+45.76%

+1.43%

+64.57%

+69.27%

−16.63%

Today

+0.88%

+3.29%

+2.97%

+4.12%

+3.25%

+4.62%

Company	Mkt cap	Price	Today
Amgen Inc.AMGN · Drug Manufacturers - General	237.31B	438.94	+3.29%
AstraZeneca PLCAZN · Drug Manufacturers - General	261.82B	168.82	+2.97%
Biogen Inc.BIIB · Drug Manufacturers - General	35.92B	243.10	+4.12%
Merck & Co., Inc.MRK · Drug Manufacturers - General Odds	365.88B	148.30	+3.25%
SanofiSNY · Drug Manufacturers - General	99.20B	41.40	+4.62%
Recordati Industria Chimica e Farmaceutica S.p.A.REC.MI · Drug Manufacturers - General	11.01B	52.95	−0.09%
Ono Pharmaceutical Co., Ltd.4528.T · Drug Manufacturers - General	1.18T	2,503.00	+0.87%
Daiichi Sankyo Company, Limited4568.T · Drug Manufacturers - General	5.17T	2,841.00	+0.74%

Company	Mkt cap	Price	Today
AstraZeneca PLCAZN · Cambridge, United Kingdom	261.82B	168.82	+2.97%
Amgen Inc.AMGN · Thousand Oaks, CA	237.31B	438.94	+3.29%
Roche Holding AGROP.SW · Basel, Switzerland	311.06B	390.40	+0.13%
Gilead Sciences, Inc.GILD · Foster City, CA Odds	194.07B	156.51	+2.25%
Merck & Co., Inc.MRK · Rahway, NJ Odds	365.88B	148.30	+3.25%
Novo Nordisk A/SNVO · Bagsvaerd, Denmark	173.66B	39.35	+2.42%
Pfizer Inc.PFE · New York, NY Odds	171.62B	30.11	+2.28%
AbbVie Inc.ABBV · North Chicago, IL	510.84B	289.08	+2.26%

Company	Mkt cap	Price	Today
Piramal Pharma LimitedPPLPHARMA.BO · Drug Manufacturers - Specialty & Generic	254.01B	191.70	−1.41%
AstraZeneca PLCAZN · Drug Manufacturers - General	261.82B	168.82	+2.97%
Thermo Fisher Scientific Inc.TMO · Diagnostics & Research Odds	254.15B	687.37	+1.18%
Nihon Kohden Corporation6849.T · Medical Devices	264.35B	1,652.50	−0.30%
Edwards Lifesciences CorporationE1WL34.SA · Medical Devices	240.94B	104.50	0.00%
Nippon Shinyaku Co., Ltd.4516.T · Drug Manufacturers - Specialty & Generic	233.61B	3,466.00	+0.90%
Amgen Inc.AMGN · Drug Manufacturers - General	237.31B	438.94	+3.29%
AlvotechALVO.IC · Drug Manufacturers - Specialty & Generic	224.79B	630.00	0.00%

Company	Mkt cap	Price	Today
BeOne Medicines AGONC · Basel, Switzerland	43.74B	384.50	+3.87%
Roche Holding AGRHO.DE · Basel, Switzerland	342.13B	429.40	+0.99%
Lonza Group AGLO3.F · Basel, Switzerland	47.08B	674.00	+0.60%
Sandoz Group AGSDZ.SW · Basel, Switzerland	33.39B	77.16	+0.05%
Helvetia Baloise Holding AGHBAN.SW · Basel, Switzerland	21.49B	217.00	+1.12%
Straumann Holding AG0QMV.IL · Basel, Switzerland	15.91B	95.28	+1.73%
Compagnie Financière Richemont SACFR.JO · Bellevue, Switzerland	2.06T	349,554.00	−0.18%
Glencore plc8GC.F · Baar, Switzerland	77.26B	6.59	−0.15%

Company	Mkt cap	Price	Today
AstraZeneca PLCAZN · artificial intelligence · life sciences · healthcare	261.82B	168.82	+2.97%
Novo Nordisk A/SNVO · artificial intelligence · life sciences	173.66B	39.35	+2.42%
Pfizer Inc.PFE · artificial intelligence · life sciences Odds	171.62B	30.11	+2.28%
Chugai Pharmaceutical Co., Ltd.4519.T · artificial intelligence · life sciences	10.71T	6,511.00	+1.26%
Evotec SEEVO · artificial intelligence · life sciences · healthcare	525.98M	1.4800	+4.23%
SanofiSNW.F · artificial intelligence · healthcare	88.21B	73.63	−0.05%
Caris Life Sciences, Inc.CAI · artificial intelligence · life sciences · healthcare	8.79B	31.11	+1.30%
Lunai Bioworks Inc.LNAI · artificial intelligence · life sciences · healthcare	2.33M	0.5150	+9.11%

Company	Mkt cap	Price	Today
Amgen Inc.AMGN · Correlation 0.52	237.31B	438.94	+3.29%
AstraZeneca PLCAZN · Correlation 0.52	261.82B	168.82	+2.97%
Merck & Co., Inc.MRK · Correlation 0.39 Odds	365.88B	148.30	+3.25%
SanofiSNY · Correlation 0.36	99.20B	41.40	+4.62%

Company	Mkt cap	Price	Today
Nestlé S.A.NESR.F	231.17B	89.87	+0.30%
PFIZER INC.PFE.F	152.18B	26.70	−0.78%
Allianz SEALV.F	164.69B	434.20	+0.46%
JOHNSON & JOHNSONJNJ.F	555.96B	230.70	+0.26%
MICROSOFT CORP.MSF.F	3.49T	470.00	−0.50%

Seeking Alpha·1d ago

Novartis: The Sell-Off Creates An Attractive Entry Point

Novartis Q3 earnings Oct 27: revenue growth, oncology strength & Cosentyx EMA news. Click here to read my most recent analysis of NVS stock. - On October 27, Novartis will report its results for the third quarter. - As a reminder, its Q2…

Oncodaily - Oncology News·18h agoPositive

Emad Shash: Welcoming Novartis Egypt Leaders to Cairo University’s Breast Cancer Center

Emad Shash, Leading Cancer Researcher and Director at National Cancer Institute, shared on LinkedIn: It was a great pleasure today to welcome Jihane Hatem El Murr, Country President of Novartis Egypt, together with Moheyeldin Magdy Head of…

pharmaphorum·2d ago

Novartis abandons Fabhalta trial in lupus nephritis

A failed phase 2 study has undermined Novartis' hopes of extending the approved indications for its oral complement inhibitor Fabhalta to include lupus nephritis. According to an update on the clinicaltrials.gov registry website, Novartis…

TradingView·1d ago

Enterprise value to revenue forward of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology,…

@insidermonkey·1d agoNegative

Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much?

Novartis is generating impressive sales from newer medicines, but generic competition is consuming much of that growth. Its earnings valuation makes the gap difficult to ignore. The stock closed at $143.75 on October 9, with Yahoo…

Seeking Alpha·4d agoNegative

Novartis halts mid-stage trial for kidney drug, Fabhalta, in lupus nephritis

Novartis (NVS) ends a mid-stage trial for kidney drug Fabhalta (iptacopan) in lupus nephritis because of strategic considerations. Read more here. TBE/iStock Editorial via Getty Images Novartis (NVS) has terminated a mid-stage trial for…

@novartis·4d agoPositive

Novartis in Society Integrated Report

Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story. Visit our resource hub for information around clinical trials, our products and innovation pipeline. Learn about our commitment to…

@novartis·4d ago

The Novartis US Foundation

SRN News·4d agoNegative

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

• The trial was evaluating whether the oral medication was safe and effective for treating lupus nephritis when added to standard medical care • Lupus nephritis is a severe inflammation of the kidneys caused by the autoimmune disease lupus…

@novartis·4d ago

Novartis commitment to patients and caregivers

Days on the list

30 d

1 yr

Best

Trending

—

Install

Novartis AG

Key statistics

Against its peers

Latest news